ECM
SGMO

ETrade Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

ETrade Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$332K Sell
35,028
-2,316
-6% -$25K 0.01% 689
2020
Q2 		$335K Buy
+37,344
New +$346K 0.01% 633

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ETrade Capital Management's SGMO Position: Q3 2020 in Review

ETrade Capital Management reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 6.2% in Q3 2020, selling an estimated $25K and leaving 35,028 shares worth $332K. The position accounts for 0.01% of the portfolio, ranked #689.

ETrade Capital Management first reported a position in SGMO in Q2 2020 and has held it in 2 quarters since. The position peaked at $335K in Q2 2020. 210 funds tracked by Wall St. Rank hold SGMO as of Q3 2020.

  • ETrade Capital Management held 35,028 shares of SANGAMO THERAPEUTICS INC worth $332K as of Q3 2020.
  • ETrade Capital Management sold 2,316 SANGAMO THERAPEUTICS INC shares in Q3 2020, an estimated $25K.
  • SANGAMO THERAPEUTICS INC made up 0.01% of ETrade Capital Management's portfolio in Q3 2020, its #689 holding.
  • ETrade Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2020 and has held it in 2 quarters since.
  • ETrade Capital Management's SANGAMO THERAPEUTICS INC position peaked at $335K in Q2 2020.
  • 210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.